Correspondence 0001104659-24-051633 from Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc.
Date: April 25, 2024 · CIK: 0001781983 · Accession: 0001104659-24-051633
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278485
Letter
APREA THERAPEUTICS, INC.
3805 Old Easton Road
Doylestown, PA 18902
April 25, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Chris Edwards
Re: Aprea Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-278485
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278485), so that it may become effective at 4:30 p.m. Eastern Time on April 29, 2024, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Fahd Riaz, Esq. of DLA Piper LLP (US), counsel to the Company, at (215) 656-3316, with any comments or questions regarding the Registration Statement.
Very truly yours,
APREA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
APREA THERAPEUTICS, INC.
3805 Old Easton Road
Doylestown, PA 18902
April 25, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Chris Edwards
Re:
Aprea Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-278485
Request for Acceleration
Ladies and Gentlemen:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the “Registrant”)
hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278485), so
that it may become effective at 4:30 p.m. Eastern Time on April 29, 2024, or as soon as practicable thereafter, or at such later
time as the Registrant or its counsel may orally request via telephone call to the staff.
The
cooperation of the staff in meeting the timetable described above is very much appreciated.
Please
call Fahd Riaz, Esq. of DLA Piper LLP (US), counsel to the Company, at (215) 656-3316, with any comments or questions regarding
the Registration Statement.
Very truly yours,
APREA THERAPEUTICS, INC.
By:
/s/ Oren Gilad
Name:
Oren Gilad
Title:
Chief Executive Officer
cc:
Patrick O’Malley, Esq., DLA Piper LLP (US)
Dylan Caplan, Esq., DLA Piper LLP (US)